Supplementary Table 1. Overview of clinical trials on various CD47-blocking antibodies.

Agent	Regimen	Mechanism	Selected population for trials	Clinical trials ID	Company
AO-176 (Humanized IgG2 anti-CD47 mAb)	AO-176 OR AO-176 + paclitaxel OR AO-176 + pembrolizumab AO-176 OR AO-176 + either dexamethasone OR dexamethasone + bortezomib	Designed for minimal red blood cell binding, preferential tumor cell binding (acidic microenvironment), and some direct tumor-cell kill (not strictly ADCC).	Solid tumors, multiple myeloma (phase I/II)	NCT03834948 NCT04445701	Arch Oncology
Magrolimab (also known as Hu5F9-G4) (Humanized IgG4 anti-CD47 mAb)	Magrolimab + daratumumab + pomalidomide + dexamethasone + bortezomib Magrolimab OR magrolimab + azacitidine Magrolimab + rituximab OR rituximab + gemcitabine + oxaliplatin Magrolimab + pembrolizumab + 5-FU + platinum OR magrolimab + docetaxe Magrolimab + docetaxel OR Magrolimab + rituximab Magrolimab + azacitidine OR venetoclax + azacididine	Blocks CD47 "don't eat me" signal on cancer cells, enabling macrophage phagocytosis; built-in "priming" dose strategy because CD47 on RBCs leads to their efferocytic removal.	Hematologic malignancies (AML, MDS), solid tumors, NHL, and HNSCC. (phase I) (phase I/II) (phase II) (phase II) (phase III)	NCT04892446 NCT03248479 NCT02953509 NCT04854499 NCT04827576 NCT04778397 NCT04313881 NCT04788043	Gilead Sciences Stanford University, Merck Sharp &

https://doi.org/10.3390/xxxxx

	Magrolimab + pembrolizumab		Hodgkin's lymphoma (phase II)		Dohme Corp.
AK117 (Also known as Ligufalimab) (Humanized IgG4 anti-CD47 mAb)	AK117 monotherapy AK117 + Azacitidine	Demonstrates strong CD47 binding/blockade, with significantly lower hemagglutination and erythro-phagocytosis compared to Magrolimab in non-clinical models.	Solid tumors + hematologic malignancies, (phase I) (phase I/II)	NCT04728334 NCT04349969 CTR20211305	Akeso
CC-90002 (Humanized IgG4 anti-CD47 mAb)	CC-90002 + Rituximab	Epitope and scaffold engineered to reduce RBC binding; however, clinical monotherapy results were suboptimal.	Hematologic malignancies	NCT02367194	Celgene
IBI188 (Also known as Letaplimab) (Humanized IgG4 anti-CD47 mAb)	IBI188 + Azacitidine, OR IBI188 + decitabine IBI188 Monotherapy, OR IBI188 + rituximab Monotherapy	Anti-CD47 mAb aimed for an improved binding profile and tolerability.	Trials in NHL, AML, MDS, advanced solid cancer (phase I/II) (phase I) (phase I)	CTR20200938 NCT03717103 NCT03763149	Innovent Biologics
DSP-107 (SIRPα - 4-1BBL) (Humanized bi-functional, trimeric, fusion protein-bsAb)	Monotherapy, OR DSP-107 + atezolizumab	A first-in-class CD47 and 4-1BB targeting multifunctional immune-recruitment protein	Advanced solid cancer, non-small cell lung cancer (phase I)	NCT04440735	Kahr medical
IBI322 (Recombinant anti-human	IBI322 monotherapy, OR	Combining innate-immunity checkpoint (CD47) with adaptive checkpoint (PD-L1) in a single	Advanced malignant tumors,	NCT04328831 NCT04912466	Innovent Biologics

CD47/PD-L1 bispecific antibody-bsAb)	IBI322+ azacitidine/decitabine	molecule, promising early responses (~20 % PR in one cohort).	hematologic malignancies that failed standard treatment, locally advanced, unresectable, or metastatic tumors (Phase 1)	NCT04795128 NCT05148442	(Suzhou) Co. Ltd.

* AML: Acute myeloid leukemia; MDS: Myelodysplastic syndromes; HNSCC: head and neck squamous cell carcinoma; NHL: Non-Hodgkin lymphoma